First new drug for IBS
by Gary Finnegan – Emerging uses of EMA Approved Drugs – The EMA has given the green light for the first medicine specifically for irritable bowel syndrome (IBS)… read more.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – The EMA has given the green light for the first medicine specifically for irritable bowel syndrome (IBS)… read more.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – There’s a new man at the helm of the European Medicine Agency’s most influential committee: Dr Tomas… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Adalimumab appears to be effective in maintaining remission among some pediatric patients with Crohn’s disease.
by Bruce Sylvester – Emerging use of FDA Approved Drugs – Maraviroc, an antiretroviral drugin the treatment of HIV, significantly reduces the incidence of graft-versus-host disease (GvHD) among… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – In some patients severe aplastic anemia who have failed standard therapies, eltrombopag appears to raise blood cell… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Botulinum toxin treatment appears to improve tremor in the arms and hands of persons with multiple sclerosis… read more.
by Bruce Sylvester – Older seniors, aged 85 and over, show a high burden of respiratory disease, researchers reported on September 3, 2012 at the European Respiratory Society’s… read more.
by Bruce Sylvester – Obese persons with excess visceral fat appear to be at an increased risk of developing Type 2 diabetes,
by Bruce Sylvester – taken from The British Medical Journal (BMJ) – Contradicting previous research, researchers from a study of over 44,000 women in England report that treatment… read more.
by Bruce Sylvester – take from The Journal of the American Medical Association (JAMA) – Among patients classified at intermediate risk, heart calcium scanning, known as coronary artery… read more.
by Bruce Sylvester – taken from The New England Journal of Medicine (NEJM) – Women treated with anastrozole and fulvestrant combination therapy have achieved over 6 months median… read more.
by Bruce Sylvester – taken from The Lancet – A study by Professor Peter M Rothwell, University of Oxford, UK and colleagues supports the hypothesis and adds to… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.